Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Biol Chem ; 295(50): 17158-17168, 2020 12 11.
Article in English | MEDLINE | ID: mdl-33023907

ABSTRACT

Cellular energy demands are met by uptake and metabolism of nutrients like glucose. The principal transcriptional regulator for adapting glycolytic flux and downstream pathways like de novo lipogenesis to glucose availability in many cell types is carbohydrate response element-binding protein (ChREBP). ChREBP is activated by glucose metabolites and post-translational modifications, inducing nuclear accumulation and regulation of target genes. Here we report that ChREBP is modified by proline hydroxylation at several residues. Proline hydroxylation targets both ectopically expressed ChREBP in cells and endogenous ChREBP in mouse liver. Functionally, we found that specific hydroxylated prolines were dispensable for protein stability but required for the adequate activation of ChREBP upon exposure to high glucose. Accordingly, ChREBP target gene expression was rescued by re-expressing WT but not ChREBP that lacks hydroxylated prolines in ChREBP-deleted hepatocytes. Thus, proline hydroxylation of ChREBP is a novel post-translational modification that may allow for therapeutic interference in metabolic diseases.


Subject(s)
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/biosynthesis , Gene Expression Regulation , Glucose/metabolism , Liver/metabolism , Protein Processing, Post-Translational , Animals , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/genetics , HEK293 Cells , Humans , Hydroxylation , Male , Metabolic Diseases/genetics , Metabolic Diseases/metabolism , Mice , Mice, Transgenic , Proline/genetics , Proline/metabolism
2.
Nat Commun ; 8(1): 384, 2017 08 30.
Article in English | MEDLINE | ID: mdl-28855500

ABSTRACT

The liver integrates multiple metabolic pathways to warrant systemic energy homeostasis. An excessive lipogenic flux due to chronic dietary stimulation contributes to the development of hepatic steatosis, dyslipidemia and hyperglycemia. Here we show that the oxidoreductase retinol saturase (RetSat) is involved in the development of fatty liver. Hepatic RetSat expression correlates with steatosis and serum triglycerides (TGs) in humans. Liver-specific depletion of RetSat in dietary obese mice lowers hepatic and circulating TGs and normalizes hyperglycemia. Mechanistically, RetSat depletion reduces the activity of carbohydrate response element binding protein (ChREBP), a cellular hexose-phosphate sensor and inducer of lipogenesis. Defects upon RetSat depletion are rescued by ectopic expression of ChREBP but not by its putative enzymatic product 13,14-dihydroretinol, suggesting that RetSat affects hepatic glucose sensing independent of retinol conversion. Thus, RetSat is a critical regulator of liver metabolism functioning upstream of ChREBP. Pharmacological inhibition of liver RetSat may represent a therapeutic approach for steatosis.Fatty liver is one of the major features of metabolic syndrome and its development is associated with deregulation of systemic lipid and glucose homeostasis. Here Heidenreich et al. show that retinol saturase is implicated in hepatic lipid metabolism by regulating the activity of the transcription factor ChREBP.


Subject(s)
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/metabolism , Fatty Liver/metabolism , Liver/metabolism , Oxidoreductases Acting on CH-CH Group Donors/physiology , Animals , Glucose/metabolism , Hepatocytes/metabolism , Humans , Lipid Metabolism , Male , Mice , Mice, Inbred C57BL , Oxidoreductases Acting on CH-CH Group Donors/genetics , Oxidoreductases Acting on CH-CH Group Donors/metabolism , Triglycerides/blood
3.
Nat Struct Mol Biol ; 24(1): 15-22, 2017 01.
Article in English | MEDLINE | ID: mdl-27892932

ABSTRACT

Circadian clocks are cell-autonomous oscillators regulating daily rhythms in a wide range of physiological, metabolic and behavioral processes. Feedback of metabolic signals, such as redox state, NAD+/NADH and AMP/ADP ratios, or heme, modulate circadian rhythms and thereby optimize energy utilization across the 24-h cycle. We show that rhythmic heme degradation, which generates the signaling molecule carbon monoxide (CO), is required for normal circadian rhythms as well as circadian metabolic outputs. CO suppresses circadian transcription by attenuating CLOCK-BMAL1 binding to target promoters. Pharmacological inhibition or genetic depletion of CO-producing heme oxygenases abrogates normal daily cycles in mammalian cells and Drosophila. In mouse hepatocytes, suppression of CO production leads to a global upregulation of CLOCK-BMAL1-dependent circadian gene expression and dysregulated glucose metabolism. Together, our findings show that CO metabolism is an important link between the basic circadian-clock machinery, metabolism and behavior.


Subject(s)
Carbon Monoxide/metabolism , Circadian Clocks , ARNTL Transcription Factors/metabolism , Animals , CLOCK Proteins/metabolism , Cell Line, Tumor , Drosophila melanogaster , Glucose/metabolism , Heme/metabolism , Heme Oxygenase (Decyclizing)/physiology , Homeostasis , Humans , Male , Metabolic Networks and Pathways , Mice, Inbred C57BL , Mice, Knockout , Motor Activity , Protein Binding , Transcription, Genetic , Transcriptional Activation
4.
Endocrinology ; 156(11): 4008-19, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26181104

ABSTRACT

Reduced de novo lipogenesis in adipose tissue, often observed in obese individuals, is thought to contribute to insulin resistance. Besides trapping excess glucose and providing for triglycerides and energy storage, endogenously synthesized lipids can function as potent signaling molecules. Indeed, several specific lipids and their molecular targets that mediate insulin sensitivity have been recently identified. Here, we report that carbohydrate-response element-binding protein (ChREBP), a transcriptional inducer of glucose use and de novo lipogenesis, controls the activity of the adipogenic master regulator peroxisome proliferator-activated receptor (PPAR)γ. Expression of constitutive-active ChREBP in precursor cells activated endogenous PPARγ and promoted adipocyte differentiation. Intriguingly, ChREBP-constitutive-active ChREBP expression induced PPARγ activity in a fatty acid synthase-dependent manner and by trans-activating the PPARγ ligand-binding domain. Reducing endogenous ChREBP activity by either small interfering RNA-mediated depletion, exposure to low-glucose concentrations, or expressing a dominant-negative ChREBP impaired differentiation. In adipocytes, ChREBP regulated the expression of PPARγ target genes, in particular those involved in thermogenesis, similar to synthetic PPARγ ligands. In summary, our data suggest that ChREBP controls the generation of endogenous fatty acid species that activate PPARγ. Thus, increasing ChREBP activity in adipose tissue by therapeutic interventions may promote insulin sensitivity through PPARγ.


Subject(s)
Adipocytes/metabolism , Cell Differentiation , Lipogenesis , Nuclear Proteins/metabolism , PPAR gamma/metabolism , Transcription Factors/metabolism , 3T3-L1 Cells , Adipocytes/cytology , Adipocytes/drug effects , Animals , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors , Cell Line , Gene Expression , Glucose/metabolism , Glucose/pharmacology , HEK293 Cells , Humans , Immunoblotting , Mesenchymal Stem Cells/metabolism , Mice , Nuclear Proteins/genetics , Protein Isoforms/genetics , Protein Isoforms/metabolism , RNA Interference , Reverse Transcriptase Polymerase Chain Reaction , Transcription Factors/genetics
5.
Mol Cell Biol ; 33(20): 4068-82, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23959802

ABSTRACT

Retinoids are vitamin A (retinol) derivatives and complex regulators of adipogenesis by activating specific nuclear receptors, including the retinoic acid receptor (RAR) and retinoid X receptor (RXR). Circulating retinol-binding protein 4 (RBP4) and its membrane receptor STRA6 coordinate cellular retinol uptake. It is unknown whether retinol levels and the activity of RAR and RXR in adipocyte precursors are linked via RBP4/STRA6. Here, we show that STRA6 is expressed in precursor cells and, dictated by the apo- and holo-RBP4 isoforms, mediates bidirectional retinol transport that controls RARα activity and subsequent adipocyte differentiation. Mobilization of retinoid stores in mice by inducing RBP4 secretion from the liver activated RARα signaling in the precursor cell containing the stromal-vascular fraction of adipose tissue. Retinol-loaded holo-RBP4 blocked adipocyte differentiation of cultured precursors by activating RARα. Remarkably, retinol-free apo-RBP4 triggered retinol efflux that reduced cellular retinoids, RARα activity, and target gene expression and enhanced adipogenesis synergistically with ectopic STRA6. Thus, STRA6 in adipocyte precursor cells links nuclear RARα activity to the circulating RBP4 isoforms, whose ratio in obese mice was shifted toward limiting the adipogenic potential of their precursors. This novel cross talk identifies a retinol-dependent metabolic function of RBP4 that may have important implications for the treatment of obesity.


Subject(s)
Adipocytes/metabolism , Adipose Tissue/metabolism , Membrane Proteins/metabolism , Obesity/metabolism , Receptors, Retinoic Acid/metabolism , Retinol-Binding Proteins, Plasma/metabolism , Vitamin A/blood , 3T3-L1 Cells , Adipocytes/cytology , Adipogenesis/genetics , Adipose Tissue/cytology , Animals , Cell Differentiation , Gene Expression Regulation , Homeostasis , Liver/cytology , Liver/metabolism , Male , Membrane Proteins/genetics , Mice , Mice, Transgenic , Obesity/genetics , Obesity/pathology , Receptors, Retinoic Acid/genetics , Retinoic Acid Receptor alpha , Retinoid X Receptors/genetics , Retinoid X Receptors/metabolism , Retinol-Binding Proteins, Plasma/genetics , Signal Transduction
6.
Mol Cell Biol ; 32(21): 4363-74, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22927645

ABSTRACT

The GTPase ADP-ribosylation factor-related protein 1 (ARFRP1) is located at the trans-Golgi compartment and regulates the recruitment of Arf-like 1 (ARL1) and its effector golgin-245 to this compartment. Here, we show that liver-specific knockout of Arfrp1 in the mouse (Arfrp1(liv-/-)) resulted in early growth retardation, which was associated with reduced hepatic insulin-like growth factor 1 (IGF1) secretion. Accordingly, suppression of Arfrp1 in primary hepatocytes resulted in a significant reduction of IGF1 release. However, the hepatic secretion of IGF-binding protein 2 (IGFBP2) was not affected in the absence of ARFRP1. In addition, Arfrp1(liv-/-) mice exhibited decreased glucose transport into the liver, leading to a 50% reduction of glycogen stores as well as a marked retardation of glycogen storage after fasting and refeeding. These abnormalities in glucose metabolism were attributable to reduced protein levels and intracellular retention of the glucose transporter GLUT2 in Arfrp1(liv-/-) livers. As a consequence of impaired glucose uptake into the liver, the expression levels of carbohydrate response element binding protein (ChREBP), a transcription factor regulated by glucose concentration, and its target genes (glucokinase and pyruvate kinase) were markedly reduced. Our data indicate that ARFRP1 in the liver is involved in the regulation of IGF1 secretion and GLUT2 sorting and is thereby essential for normal growth and glycogen storage.


Subject(s)
ADP-Ribosylation Factors/metabolism , Glucose Transporter Type 2/metabolism , Insulin-Like Growth Factor I/metabolism , Liver Glycogen/metabolism , Liver/metabolism , ADP-Ribosylation Factors/deficiency , ADP-Ribosylation Factors/genetics , Animals , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors , Carbohydrate Metabolism , Cell Proliferation , Cells, Cultured , Glucose/metabolism , Golgi Apparatus/metabolism , Hepatocytes/metabolism , Insulin-Like Growth Factor Binding Protein 2/biosynthesis , Insulin-Like Growth Factor Binding Protein 2/metabolism , Insulin-Like Growth Factor I/biosynthesis , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Nuclear Proteins/biosynthesis , RNA Interference , RNA, Small Interfering , Transcription Factors/biosynthesis
7.
Diabetes ; 61(2): 513-23, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22210316

ABSTRACT

In the current study, we investigated the importance of histone deacetylase (HDAC)6 for glucocorticoid receptor-mediated effects on glucose metabolism and its potential as a therapeutic target for the prevention of glucocorticoid-induced diabetes. Dexamethasone-induced hepatic glucose output and glucocorticoid receptor translocation were analyzed in wild-type (wt) and HDAC6-deficient (HDAC6KO) mice. The effect of the specific HDAC6 inhibitor tubacin was analyzed in vitro. wt and HDAC6KO mice were subjected to 3 weeks' dexamethasone treatment before analysis of glucose and insulin tolerance. HDAC6KO mice showed impaired dexamethasone-induced hepatic glucocorticoid receptor translocation. Accordingly, dexamethasone-induced expression of a large number of hepatic genes was significantly attenuated in mice lacking HDAC6 and by tubacin in vitro. Glucose output of primary hepatocytes from HDAC6KO mice was diminished. A significant improvement of dexamethasone-induced whole-body glucose intolerance as well as insulin resistance in HDAC6KO mice compared with wt littermates was observed. This study demonstrates that HDAC6 is an essential regulator of hepatic glucocorticoid-stimulated gluconeogenesis and impairment of whole-body glucose metabolism through modification of glucocorticoid receptor nuclear translocation. Selective pharmacological inhibition of HDAC6 may provide a future therapeutic option against the prodiabetogenic actions of glucocorticoids.


Subject(s)
Dexamethasone/pharmacology , Gluconeogenesis/drug effects , Histone Deacetylases/physiology , Liver/metabolism , Acetylation , Active Transport, Cell Nucleus , Adipose Tissue/metabolism , Animals , Corticosterone/blood , Glucose/metabolism , Histone Deacetylase 6 , Histones/metabolism , Lipopolysaccharides/pharmacology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Monocytes/metabolism , Phosphoenolpyruvate Carboxykinase (GTP)/physiology , Receptors, Glucocorticoid/metabolism
8.
Patient Educ Couns ; 85(3): 468-74, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21600724

ABSTRACT

OBJECTIVE: To gain deep insight into what it means for patients to live with drug-treated hypertension and to understand the implications for the doctors' influence on patients' adherence. METHODS: Group discussions with 43 drug-treated hypertensive patients. Documentary method was used for interpretative analysis. RESULTS: Four basic phenomena were identified (fear, ignorance, reluctance to discuss matters with the doctor, impact of illness experiences), which resulted in different types of action patterns: (1) the assertive actor, (2) the unconscious avoider, and (3) the inconsistent actor. The types of action patterns do not refer to any implications for adherence. The patients' action does not indicate their preferred model of doctor-patient interaction or their acceptance of taking medication. CONCLUSION: Adherence must not be seen as meaningless behaviour, which can simply be learned, but rather as the result of subjective experiences on living with hypertension and the ability to accept the diagnosis and its treatment. PRACTICE IMPLICATIONS: It is premature to initiate therapy straight after the diagnosis, before the patient is prepared to take the tablets. Supporting adherence means to stay in dialogue and to give the time, privacy and patience to enable patients to overcome their inhibitions of asking and to accept the therapy.


Subject(s)
Antihypertensive Agents/therapeutic use , Hypertension/drug therapy , Hypertension/psychology , Medication Adherence , Physician-Patient Relations , Adult , Aged , Fear , Female , Health Knowledge, Attitudes, Practice , Humans , Information Seeking Behavior , Male , Middle Aged , Primary Health Care , Qualitative Research , Sickness Impact Profile
SELECTION OF CITATIONS
SEARCH DETAIL